| Trial | Treatments | Patients | Method |
|---|
| ENDEAVOR, 2016 | carfilzomib with dexamethasone (n=464) vs. bortezomib with dexamethasone (n=465) | patients with relapsed or refractory multiplemyeloma who had one to three previous treatments | open-label Sample size: 464/465 Primary endpoint: PFS FU duration: |
| ASPIRE, 2014 | carfilzomib with lenalidomide and dexamethasone (n=-9) vs. lenalidomide and dexamethasone alone (n=-9) | patients with relapsed multiple myeloma | open-label Sample size: -9/-9 Primary endpoint: PFS FU duration: |
| FOCUS, 2017 | carfilzomib monotherapy (n=157) vs. low-dose corticosteroids and optional cyclophosphamide (n=158) | relapsed and refractory multiple myeloma (RRMM) | open-label Parallel groups Sample size: 157/158 Primary endpoint: OS FU duration: |
| ECOG-ACRIN | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| CLARION | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
